title: Biomodulatory metronomic therapy in stage IV melanoma is well-tolerated and may induce prolonged progression-free survival, a phase I trial.
authors.affiliation: Department of Internal Medicine III, Haematology & Oncology, University Hospital of Regensburg, Regensburg, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Hart
authors.affiliation: Department of Internal Medicine III, Haematology & Oncology, University Hospital of Regensburg, Regensburg, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Vogelhuber
authors.affiliation: Department of Dermatology, University Hospital of Regensburg, Regensburg, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Hafner
authors.affiliation: Department of Dermatology, University Hospital of Regensburg, Regensburg, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Landthaler
authors.affiliation: Department of Dermatology, University Hospital of Regensburg, Regensburg, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Berneburg
authors.affiliation: Department of Dermatology, University Hospital of Regensburg, Regensburg, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Haferkamp
authors.affiliation: Department of Internal Medicine III, Haematology & Oncology, University Hospital of Regensburg, Regensburg, Germany.
authors.forename: W
authors.initials: W
authors.lastname: Herr
authors.affiliation: Department of Internal Medicine III, Haematology & Oncology, University Hospital of Regensburg, Regensburg, Germany. albrecht.reichle@ukr.de.
authors.forename: A
authors.initials: A
authors.lastname: Reichle
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents